Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-04-25 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
苏州西瑞玛斯化学品有限公司2022年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets, income statements, cash flow statements, and notes to the financial statements. It includes figures for current and previous periods, comprehensive financial data, and signatures of responsible accounting personnel. The length is substantial (15,000 characters), and the content is the actual financial report, not just an announcement or certification. The presence of full financial statements and notes indicates this is a comprehensive annual financial report. Therefore, the document is classified as an Annual Report (10-K). FY 2023
2023-04-25 Chinese
苏州浩欧博生物医药销售有限公司2022年年度财务报表
Regulatory Filings
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2022 annual report summary of 江苏浩欧博生物医药股份有限公司, containing detailed financial data for the year 2022, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and risk factors. It includes comprehensive management discussion and analysis, financial metrics, and company operations. The length is over 14,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance, which corresponds to the Annual Report (10-K) category. FY 2022
2023-04-25 Chinese
江苏浩欧博生物医药股份有限公司关于第二届董事会第二十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on the proposal to reappoint the audit firm for the 2023 fiscal year. It references regulatory rules related to independent directors and governance but does not contain any financial statements or audit results itself. The document is short (694 characters) and serves as an approval or opinion related to an agenda item for a board meeting, not the audit report or annual report itself. Therefore, it is best classified as Board/Management Information (MANG), which covers announcements related to board matters and management decisions.
2023-04-25 Chinese
华泰联合证券关于对江苏浩欧博生物医药股份有限公司2022年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度募集资金存放和使用情况专项核查报告" which translates to a "2022 Annual Special Inspection Report on the Deposit and Use of Raised Funds". It is issued by Huatai United Securities Co., Ltd., the sponsor institution for Jiangsu Haoubo Biopharmaceutical Co., Ltd.'s initial public offering. The document details the amount of funds raised, their deposit, usage, management, and related audit opinions. It includes detailed financial data on the raised funds, their allocation, and compliance with regulatory requirements. The document is a specialized audit and verification report focusing on the use and management of raised funds, not a full annual report or earnings release. It is a standalone audit-related report concerning regulatory compliance and fund usage, fitting the definition of an Audit Report / Information (AR). The document length (7943 characters) and detailed financial data support this classification rather than a brief announcement or a general regulatory filing. FY 2022
2023-04-25 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司2022年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度现场检查报告" (2022 Annual On-site Inspection Report) issued by the sponsor institution 华泰联合证券有限责任公司 regarding 江苏浩欧博生物医药股份有限公司. It details the on-site inspection covering governance, internal controls, information disclosure, related party transactions, fundraising usage, and operational status for the year 2022. The report includes regulatory references, findings, and recommendations but does not contain full financial statements or quarterly data. It is a standalone audit/inspection report related to regulatory compliance and internal controls rather than a full annual report or earnings release. The document length is 4291 characters, which is relatively short but contains substantive inspection content rather than just an announcement. Therefore, it fits best under Audit Report / Information (AR). FY 2022
2023-04-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.